AgomAb Therapeutics NV AGMB
—
10.51
(0.07)
(0.66%)
as of 25 Sep
- Market cap
- $521.1M
- P/E
- —
Follow AGMB
| Dec '24 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|
Current Ratio |
19.05 | 13.99 | 6.52 | 12.88 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
Debt/Assets |
0.62% | 0.65% | 0.65% | 0.31% |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.00 |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 |
Capex/Depreciation |
(2.17) | 0.00 | 0.04 | 0.00 |
Intangible Assets out of Total Assets |
0.14 | 0.17 | 0.19 | 0.10 |
Share Based Compensation of Revenue |
— | — | — | 0.00% |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow |
(51.40) | (45.08) | (13.46) | (34.78) |
Working Capital |
178.24 | 144.36 | 116.14 | 277.20 |
Capital Expenditures |
(0.73) | — | 0.00 | — |
Net Current Asset Value |
168.34 | 133.62 | 111.37 | 270.83 |
| Other line items | ||||
Quick Ratio |
18.79 | 13.63 | 6.27 | 12.55 |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Capex per Share |
0.00 | — | 0.00 | — |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates